Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Dunlop A. Sinclair. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Dunlop A. Sinclair has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APLS / Apellis Pharmaceuticals, Inc. Director 158,393
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Dunlop A. Sinclair. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APLS / Apellis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APLS / Apellis Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Sales APLS / Apellis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APLS / Apellis Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-03-19 APLS Dunlop A. Sinclair 18,681 57.1790 18,681 57.1790 1,068,161 349 24.0600 -618,695 -57.92
2023-12-01 APLS Dunlop A. Sinclair 24,000 61.1350 24,000 61.1350 1,467,240
2023-11-17 APLS Dunlop A. Sinclair 8,894 49.9910 8,894 49.9910 444,620
2023-10-17 APLS Dunlop A. Sinclair 24,000 49.0000 24,000 49.0000 1,176,000
2022-09-08 APLS Dunlop A. Sinclair 15,000 65.0000 15,000 65.0000 975,000
2022-08-11 APLS Dunlop A. Sinclair 30,000 65.6300 30,000 65.6300 1,968,900
2022-06-27 APLS Dunlop A. Sinclair 1,341 46.7881 1,341 46.7881 62,743
2022-06-23 APLS Dunlop A. Sinclair 15,000 45.0000 15,000 45.0000 675,000
2021-05-20 APLS Dunlop A. Sinclair 5,773 48.1000 5,773 48.1000 277,681
2021-05-19 APLS Dunlop A. Sinclair 7,612 50.0000 7,612 50.0000 380,600
2021-05-18 APLS Dunlop A. Sinclair 64,179 51.6600 64,179 51.6600 3,315,487
2021-05-18 APLS Dunlop A. Sinclair 14,216 52.6300 14,216 52.6300 748,188
2021-05-18 APLS Dunlop A. Sinclair 36,387 53.7800 36,387 53.7800 1,956,893
2021-05-18 APLS Dunlop A. Sinclair 22,318 54.5700 22,318 54.5700 1,217,893
2021-05-18 APLS Dunlop A. Sinclair 1,200 52.0100 1,200 52.0100 62,412
2021-05-18 APLS Dunlop A. Sinclair 10,388 53.5000 10,388 53.5000 555,758
2021-05-18 APLS Dunlop A. Sinclair 800 54.0200 800 54.0200 43,216
2020-12-14 APLS Dunlop A. Sinclair 7,654 53.8600 7,654 53.8600 412,244
2020-12-14 APLS Dunlop A. Sinclair 17,132 55.0100 17,132 55.0100 942,431
2020-12-14 APLS Dunlop A. Sinclair 214 56.2500 214 56.2500 12,038
2020-12-07 APLS Dunlop A. Sinclair 9,094 50.4100 9,094 50.4100 458,429
2020-12-07 APLS Dunlop A. Sinclair 9,470 51.0000 9,470 51.0000 482,970
2020-12-04 APLS Dunlop A. Sinclair 5,052 50.0400 5,052 50.0400 252,802
2020-12-04 APLS Dunlop A. Sinclair 1,384 51.0500 1,384 51.0500 70,653
2019-12-20 APLS Dunlop A. Sinclair 25,000 29.5300 25,000 29.5300 738,250
2019-12-19 APLS Dunlop A. Sinclair 54,110 28.9900 54,110 28.9900 1,568,649
2019-12-19 APLS Dunlop A. Sinclair 31,000 29.5100 31,000 29.5100 914,810
2019-12-18 APLS Dunlop A. Sinclair 25,890 28.5500 25,890 28.5500 739,160

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Dunlop A. Sinclair as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-03 2025-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 6,267 158,393 4.12
2024-09-24 2024-09-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,600 152,126 3.12 13.19 60,674 2,006,542
2024-09-17 2024-09-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -7,524 100,000 -7.00 36.79 -276,808 3,679,000
2024-09-17 2024-09-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -29,476 107,524 -21.52 36.09 -1,063,789 3,880,541
2024-07-01 2024-06-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 900 134,418 0.67 13.19 11,871 1,772,973
2024-06-21 2024-06-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,695 136,998 -1.22 39.63 -67,173 5,429,231
2024-06-21 2024-06-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -35,305 138,693 -20.29 39.22 -1,384,662 5,439,539
2024-04-15 2024-04-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 1,500 133,518 1.14 13.19 19,785 1,761,102
2024-03-20 2024-03-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -18,681 173,998 -9.70 57.18 -1,068,161 9,949,032
2024-01-02 2024-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 3,341 132,018 2.60
2023-12-15 2023-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,274 128,677 5.13 13.19 82,754 1,697,250
2023-12-05 2023-12-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -24,000 192,679 -11.08 61.14 -1,467,240 11,779,431
2023-11-21 2023-11-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -8,894 122,403 -6.77 49.99 -444,620 6,119,048
2023-11-21 2023-10-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -24,000 216,679 -9.97 49.00 -1,176,000 10,617,271
2023-04-05 2023-04-03 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 131,297 -0.38 74.05 -37,025 9,722,543
2023-03-02 2023-03-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 131,797 -0.38 65.33 -32,665 8,610,298
2023-02-02 2023-02-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 132,297 -0.38 52.61 -26,305 6,960,145
2023-01-05 2023-01-03 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 132,797 -0.38 50.70 -25,350 6,732,808
2023-01-04 2023-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 3,867 133,297 2.99
2022-12-02 2022-12-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 129,430 -0.38 49.93 -24,965 6,462,440
2022-11-03 2022-11-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -500 129,930 -0.38 60.83 -30,415 7,903,642
2022-09-08 2022-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -15,000 240,679 -5.87 65.00 -975,000 15,644,135
2022-08-26 2022-08-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,306 130,430 3.41 13.19 56,796 1,720,372
2022-08-17 2022-08-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 25,394 126,124 25.21 14.00 355,516 1,765,736
2022-08-12 2022-08-11 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -30,000 255,679 -10.50 65.63 -1,968,900 16,780,213
2022-07-22 2022-07-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 9,606 100,730 10.54 14.00 134,484 1,410,220
2022-06-29 2022-06-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,341 1,341 -50.00 46.79 -62,743 62,743
2022-06-24 2022-06-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -15,000 285,679 -4.99 45.00 -675,000 12,855,555
2022-04-25 2022-04-22 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -20,000 35,000 -36.36
2022-04-25 2022-04-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 20,000 91,124 28.12 14.00 280,000 1,275,736
2022-01-04 2022-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 8,554 8,554
2022-01-04 2022-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 4,230 71,124 6.32
2021-09-13 2021-09-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -6,894 55,000 -11.14
2021-09-13 2021-09-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,894 66,894 11.49 14.00 96,516 936,516
2021-06-02 2021-06-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other 2,682 303,361 0.89
2021-06-02 2021-06-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other 13,108 73,108 21.85
2021-06-02 2021-06-01 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other -31,855 0 -100.00
2021-05-20 2021-05-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -5,773 31,855 -15.34 48.10 -277,681 1,532,226
2021-05-20 2021-05-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -7,612 300,679 -2.47 50.00 -380,600 15,033,950
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -800 308,291 -0.26 54.02 -43,216 16,653,880
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -10,388 309,091 -3.25 53.50 -555,758 16,536,368
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,200 319,479 -0.37 52.01 -62,412 16,616,103
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -22,318 37,628 -37.23 54.57 -1,217,893 2,053,360
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -36,387 59,946 -37.77 53.78 -1,956,893 3,223,896
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -14,216 96,333 -12.86 52.63 -748,188 5,070,006
2021-05-20 2021-05-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -64,179 110,549 -36.73 51.66 -3,315,487 5,710,961
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -10,000 61,894 -13.91
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 10,000 60,000 20.00 14.00 140,000 840,000
2021-04-19 2021-04-16 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -50,000 71,894 -41.02
2021-04-19 2021-04-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 50,000 50,000 14.00 700,000 700,000
2021-01-04 2021-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 27,600 27,600
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -214 174,728 -0.12 56.25 -12,038 9,828,450
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -17,132 174,942 -8.92 55.01 -942,431 9,623,559
2020-12-15 2020-12-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -7,654 192,074 -3.83 53.86 -412,244 10,345,106
2020-12-07 2020-12-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -9,470 199,728 -4.53 51.00 -482,970 10,186,128
2020-12-07 2020-12-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -9,094 209,198 -4.17 50.41 -458,429 10,545,671
2020-12-07 2020-12-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,384 218,292 -0.63 51.05 -70,653 11,143,807
2020-12-07 2020-12-04 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -5,052 219,676 -2.25 50.04 -252,802 10,992,587
2020-01-03 2020-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 27,600 27,600 30.62 845,112 845,112
2019-12-20 2019-12-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -25,000 224,728 -10.01 29.53 -738,250 6,636,218
2019-12-20 2019-12-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -31,000 249,728 -11.04 29.51 -914,810 7,369,473
2019-12-20 2019-12-19 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -54,110 320,681 -14.44 28.99 -1,568,649 9,296,542
2019-12-20 2019-12-18 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -25,890 374,791 -6.46 28.55 -739,160 10,700,283
2019-01-03 2019-01-01 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 17,580 17,580
2018-05-09 2018-05-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other 94,357 280,728 50.63
2017-11-13 2017-11-13 4 APLS Apellis Pharmaceuticals, Inc.
Series E Preferred Stock
C - Conversion -6,078 0 -100.00
2017-11-13 2017-11-13 4 APLS Apellis Pharmaceuticals, Inc.
Series D Preferred Stock
C - Conversion -31,478 0 -100.00
2017-11-13 2017-11-13 4 APLS Apellis Pharmaceuticals, Inc.
Series C Preferred Stock
C - Conversion -150,023 0 -100.00
2017-11-13 2017-11-13 4 APLS Apellis Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -213,100 0 -100.00
2017-11-13 2017-11-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
C - Conversion 400,679 400,679
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
372,742
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
372,742
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)